XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.4
Condensed Consolidated Statements of Cashflows (Unaudited) - USD ($)
 9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities:        
Net income (loss) $ 10,864,149 $ (47,402,959) $ (14,710,460) $ (34,268,912)
Adjustments to reconcile net loss to net cash used in operating activities:        
Change in fair value of derivative liabilities (300,885) (303,593) 451,351 685,415
Change in derivative liability for authorized shares shortfall 159,633,797 43,406,183 170,319,590 18,921,537
Depreciation and amortization     45,282
Interest and amortization of debt discount 2,157,964 3,607,210 5,139,321 4,716,970
(Gain) loss on conversion of convertible notes payable 880 (882) (882) 603,529
Gain on settlement of convertible notes payable and accrued interest, warrants and accounts payable and cancelation of common shares in exchange for Series Y and Series Z preferred shares and cash (173,361,276)    
Gain on settlement of convertible notes payable and accrued interest, warrants and accounts payable     (162,109,131)
Gain on forgiveness of debt (192,521) (250,000)
Share-based compensation 166,855 222,700
Expenses paid directly by non-convertible note holder on behalf of company 158,371    
Impairment on COWA advances     360,500
Impairment of investment     65,000
Loss on sale of investment in Canna Regs     91,931
Impairment loss on software costs     196,315
Preferred stock issuance costs     5,585,594
Changes in operating assets and liabilities:        
Prepaid expenses 97,132 1,975 (95,157) 12,025
Advance to COWA, net     (360,500)
Security deposit     36,000
Accounts payable and accrued expenses 187,022 (119,176) 77,520 557,360
Accrued payroll and related expenses 173,243 94,180 140,005 732,027
Deferred revenue 25,000    
Net cash used in operating activities (390,269) (717,062) (1,037,843) (1,797,227)
Cash flows from investing activities:        
Proceeds from sale of Reg Tech and High Times     90,981
Net cash provided by investing activities     90,981
Cash flows from financing activities:        
Bank overdrafts (13,678) (13,749) 13,749
Proceeds from sale of Series X preferred shares 200,000   321,000
Proceeds from sale of Series B preferred shares and warrants     1,407,500
Proceeds from exercise of warrants     172,949
Proceeds from issuance of convertible notes payable 637,000 637,000 549,000
Proceeds from issuance of non-convertible notes payable 357,053 132,911 82,911 175,000
Repayment of non-convertible notes payable (39,641) (39,641) (45,400)
Proceeds from advances 28,991 3,696
Proceeds from PPP note payable     50,000
Repayments of advances (20,178) (3,009) (595,000)
Cash paid in settlement of debt and warrants (176,000)    
Net cash provided by financing activities 389,866 716,592 1,038,208 1,677,798
Net decrease in cash (403) (470) 365 (28,448)
Cash, beginning of period 1,485 1,120 1,120 29,568
Cash, end of period 1,082 650 1,485 1,120
Supplemental disclosures of cash flow information:        
Cash paid during period for interest 1,600 218,500
Cash paid during period for taxes
Supplemental disclosure of non-cash investing and financing activities:        
Common shares issued upon conversion of convertible notes and accrued interest 133,002 370,755    
Issuance of common shares previously to be issued 1,006 37,160    
Reduction of derivative liabilities stemming from settlement of convertible notes payable, accrued interest and warrants in exchange for Series Y preferred shares 4,834,911    
Reduction of derivative liabilities stemming from settlement of convertible notes payable and accrued interest and cancelation of common shares and warrants for cash 169,815,037    
Series Z preferred shares issued as equity kicker for note payable 867,213    
Series Z preferred shares issued as part of settlement agreement 6,530,868    
Settlement paid directly by CEO on behalf of company 1,000,000    
Settlement payment made directly by CEO on behalf of company 25,000    
Issuance of common stock previously to be issued     37,160 80
Issuance of preferred Series A shares in exchange for warrants canceled     296,746
Conversions of preferred Series A shares to common shares     3,137,248
Common stock issued as origination shares     141,333
Common stock issued upon conversion of convertible notes and accrued interest     370,755 1,732,318
Common shares contributed back to the Company and promptly retired 69 69
Common stock issued in settlement of a warrant provision     437,400
Common stock issued in exercise of cashless warrants     3,998
Deemed dividend related to warrant price protection 95,002,933 95,838,488 28,933,472
Contingent beneficial conversion feature on preferred Series A shares     45,147,093
Deemed dividend resulting from exchange of preferred Series A and Series B shares for convertible notes     1,476,280
Preferred Series B shares exchanged for convertible notes     826,884
Convertible note payable issued to CFO with BCF     64,143
Derivative liability recognized as debt discount on newly issued convertible notes 528,076 573,230
Series Y preferred shares issued as settlement for convertible notes payable, accrued interest and warrants 1,314,678 13,095,636
Amortization of discount on preferred stock 34,798,923 1,074,539
Reclassify accrued interest to convertible notes payable $ 93,685 1,049,329
Recission of warrants exercised in prior year     $ 6,000